Tvardi Therapeutics Reports Positive Phase 1 Results for TTI-109, Confirming Prodrug Design and Target Engagement
TVRD sits 45% above its 52-week low of $1.5.
Summary
Tvardi Therapeutics reported positive Phase 1 clinical data for its STAT3 inhibitor TTI-109, showing improved tolerability and target engagement, paving the way for Phase 2 studies in dermatologic and GI diseases, pending additional funding.
Key Events · Product Development and Regulatory · TVRD
-
Positive Phase 1 TTI-109 Results
The study confirmed rapid prodrug conversion, equivalent exposure to TTI-101, sustained target-level exposure, and improved tolerability compared to TTI-101.
-
Evidence of STAT3 Target Engagement
Exploratory pharmacodynamic analysis showed reductions of up to 60% in STAT3-driven immune cell populations, including Th17, T follicular helper (Tfh), and B cells.
-
Advancement to Phase 2 Planned
The company plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal diseases, subject to additional funding.
-
Investor Webcast Scheduled
Tvardi management will host an investor webcast today, July 7, 2026, to discuss these results in more detail.
Analysis · TVRD · Life Sciences
Tvardi Therapeutics announced positive Phase 1 clinical trial results for TTI-109, its next-generation STAT3 inhibitor. The study confirmed successful prodrug conversion, improved tolerability compared to TTI-101, and significant pharmacodynamic evidence of STAT3 target engagement, with reductions in disease-relevant immune cell populations. These results validate the company's development strategy and support advancing TTI-109 into Phase 2 studies for dermatologic and gastrointestinal diseases. This positive clinical data is crucial for the micro-cap biotech, especially given its prior going concern warning and existing ATM program, as it directly impacts its ability to secure the additional funding required for further development.
At the time of this filing, TVRD was trading at $2.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.9M. The 52-week trading range was $1.50 to $43.65. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.